These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9505340)

  • 1. Pathogenesis and prevention of doxorubicin cardiomyopathy.
    Ferrans VJ; Clark JR; Zhang J; Yu ZX; Herman EH
    Tsitologiia; 1997; 39(10):928-37. PubMed ID: 9505340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
    Outomuro D; Grana DR; Azzato F; Milei J
    Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy.
    Simpson C; Herr H; Courville KA
    Clin J Oncol Nurs; 2004 Oct; 8(5):497-501. PubMed ID: 15515283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin-induced cardiomyopathy.
    Muggia FM; Speyer JL
    N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
    [No Abstract]   [Full Text] [Related]  

  • 10. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
    Octavia Y; Tocchetti CG; Gabrielson KL; Janssens S; Crijns HJ; Moens AL
    J Mol Cell Cardiol; 2012 Jun; 52(6):1213-25. PubMed ID: 22465037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
    Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
    Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
    Silber JH
    Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
    [No Abstract]   [Full Text] [Related]  

  • 13. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
    Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
    Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
    Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
    Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
    Ferrans VJ
    Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
    J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of mtDNA lesions in anthracycline cardiotoxicity.
    Lebrecht D; Walker UA
    Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE; Asker ME; Ali SI; el-Fattah TM
    J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.